SEARCH

SEARCH BY CITATION

References

  • 1
    Oda T, Tsuda H, Scarpa A, Sakamoto M, Hirohashi S. Mutation pattern of the p53 gene as a diagnostic marker for multiple hepatocellular carcinoma. Cancer Res 1992; 52: 36743678.
  • 2
    Oda T, Tsuda H, Scarpa A, Sakamoto M, Hirohashi S. p53 gene mutation spectrum in hepatocellular carcinoma. Cancer Res 1992; 52: 63586364.
  • 3
    Murakami Y, Hayashi K, Hirohashi S, Sekiya T. Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas. Cancer Res 1991; 51: 55205525.
  • 4
    Zhang X, Xu HJ, Murakami Y, Sachse R, Yashima K, Hirohashi S, Hu SX, et al. Deletions of chromosome 13q, mutations in retinoblastoma 1, and retinoblastoma protein state in human hepatocellular carcinoma. Cancer Res 1994; 54: 41774182.
  • 5
    Buetow KH, Murray JC, Israel JL, London WT, Smith M, Kew M, Blanquet V, et al. Loss of heterozygosity suggests tumor suppressor gene responsible for primary hepatocarcinoma. Proc Natl Acad Sci U S A 1989; 86: 88528856.
  • 6
    Zhang W, Hirohashi S, Tsuda H, Shimosato Y, Yokota J, Terada M, Sugimura T. Frequent loss of heterozygosity on chromosomes 16 and 4 in human hepatocellular carcinoma. Jpn J Cancer Res 1990; 81: 108111.
  • 7
    Tsuda H, Zhang W, Shimosato Y, Yokota J, Terada M, Sugimura T, Miyamura T, et al. Allele loss on chromosome 16 associated with progression of human hepatocellular carcinoma. Proc Natl Acad Sci USA 1990; 87: 67916794.
  • 8
    Emi M, Fujiwara Y, Nakajima T, Tsuchiya E, Tsuda H, Hirohashi S, Maeda Y, et al. Frequent loss of heterozygosity for loci on chromosome 8p in hepatocellular carcinoma, colorectal cancer, and lung cancer. Cancer Res 1992; 52: 53685376.
  • 9
    Emi M, Fujiwara Y, Ohata H, Tsuda H, Hirohashi S, Koike M, Miyaki M, et al. Allelic loss at chromosome band 8p21.3-p22 is associated with progression of hepatocellular carcinoma. Genes Chromosomes Cancer 1993; 7: 152157.
  • 10
    Hunter T, Pines J. Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell 1994; 79: 573582.
  • 11
    Serrano M, Harmon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366: 704707.
  • 12
    Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994; 264: 436440.
  • 13
    Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994; 368: 753756.
  • 14
    Xiong Y, Zhang H, Beach D. Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation. Genes Dev 1993; 7: 15721583.
  • 15
    Serrano M, Gomez-Lahoz E, DePinho RA, Beach D, Bar-Sagi D. Inhibition of Ras-induced proliferation and cellular transformation by p16INK4. Science 1995; 267: 249252.
  • 16
    Mori T, Miura K, Aoki T, Nishihara T, Mori S, Nakamura Y. Frequent somatic mutation of the MTS/CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res 1994; 54: 33963397.
  • 17
    Yoshida S, Todoroki T, Ichikawa Y, Hanai S, Suzuki H, Hori M, Fukao K, et al. Mutation of p16INK4/CDKN2 and p15INK4B/MTS2 genes in biliary tract cancers. Cancer Res 1995; 55: 27562760.
  • 18
    Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, et al. Frequent somatic mutations and homozygous deletions of the p!6 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 1994; 8: 2732.
  • 19
    Gonzalez-Zulueta M, Shibata A, Ohneseit PF, Spruck III CH, Busch C, Shamaa M, Elbaz M, et al. High frequency of chromosome 9p allelic loss and CDKN2 tumor suppressor gene alteration in squamous cell carcinoma of the bladder. J Natl Cancer Inst 1995; 87: 13831393.
  • 20
    Xu L, Sgroi D, Sterner CJ, Beauchamp RL, Pinney DM, Keel S, Ueki K, et al. Mutational analysis of CDKN2 (MTSl/pl6IHK4) in human breast carcinomas. Cancer Res 1994; 54: 52625264.
  • 21
    Sun Y, Hildesheim A, Lanier AE, Cao Y, Yao KT, Raab-Traub N, Yang CS. No point mutation but decreased expression of the p!6/MTSl tumor suppressor gene in nasopharyngeal carcinomas. Oncogene 1995; 10: 785788.
  • 22
    Igaki H, Sasaki H, Tachimori Y, Kato H, Watanabe H, Kimura T, Harada Y, et al. Mutation frequency of the p16/CDKN2 gene in primary cancers in the upper digestive tract. Cancer Res 1995; 55: 34213423.
  • 23
    Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin S, et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor pl6/CDKN2/MTSl in human cancers. Nat Med 1995; 1: 686692.
  • 24
    Herman JG, Merlo A, Mao L, Lapidus RG, Issa JPJ, Davidson NE, Sidransky D, et al. Inactivation of the CDKN2/pl6/MTSl gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995; 55: 45254530.
  • 25
    Gonzalez-Zulueta M, Bender CM, Yang AS, Nguyen T, Beart RW, Van Tornout JM, Jones PA. Methylation of the 5′ CpG island of the p!6/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res 1995; 55: 45314535.
  • 26
    Shimoyama Y, Gotoh M, Ino Y, Sakamoto M, Hirohashi S., Characterization of high-molecular-mass forms of basic fibroblast growth factor produced by hepatocellular carcinoma cells: possible involvement of basic fibroblast growth factor in hepatocarcinogenesis. Jpn J Cancer Res 1991; 82: 12631270.
  • 27
    Kanai T, Hirohashi S, Upton MP, Noguchi M, Kishi K, Makuuchi M, Yamazaki S, et al. Pathology of small hepatocellular carcinoma: a proposal for a new gross classification. Cancer 1987; 60: 810819.
  • 28
    Sakamoto M, Hirohashi S, Shimosato Y., Early stages of multistep hepatocarcinogenesis: adenomatous hyperplasia and early hepatocellular carcinoma. Hum Pathol 1991; 22: 172178
  • 29
    Hirohashi S, Sakamoto M. Hepatocellular carcinoma in the early stage. In: TobeT, KamedaH, OkudairaM, OhtoM, EndoY, MitoM, OkamotoE, et al., eds. Primary liver cancer in Japan. Tokyo, Japan: Springer-Verlag, 1992: 2530.
  • 30
    Oda T, Tsuda H, Sakamoto M, Hirohashi S. Different mutations of the p53 gene in nodule-in-nodule hepatocellular carcinoma as a evidence for multistage progression. Cancer Lett 1994; 83: 197200.
  • 31
    Xiong Y, Zhang H, Beach D. D type cyclins associate with multiple protein kinases and the DNA replication and repair factor PCNA. Cell 1992; 71: 505514.
  • 32
    Ragione FD, Russo GL, Oliva A, Mastropietro S, Mancini A, Borrelli A, Casero RA, et al. 5′-Deoxy-5′-methylthioadenosine phosphorylase and p16INK4 deficiency multiple tumor cell lines. Oncogene 1995; 10: 827833.
  • 33
    Chomczynsky P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156159.
  • 34
    Yeager T, Stadler W, Belair C, Puthenveettil J, Olopade O, Reznikoff C. Increased p16 levels correlate with pRb alterations in human urothelial cells. Cancer Res 1995; 55: 493497.
  • 35
    Blin N, Stafford DM. A general method for isolation of high-molecular -weight DNA from eukaryotes. Nucleic Acids Res 1976; 3: 23032308.
  • 36
    Ueki K, Rabio MP, Ramesh V, Correa KM, Rutter JL, van Deimling A, Buckler AJ, et al. MTS1/CDKN2 gene mutations are rare in primary human astrocytomas with allelic loss of chromosome 9p. Hum Mol Genet 1994; 3: 18411845.
  • 37
    Igaki H, Sasaki H, Kishi T, Sakamoto H, Tachimori Y, Kato H, Watanabe H, et al. Highly frequent homozygous deletion of the p!6 gene in esophageal cancer cell lines. Biochem Biophys Res Commun 1994; 203: 10901095.
  • 38
    Takayama T, Makuuchi M, Hirohashi S, Sakamoto M, Okazaki S, Takayasu K, Kosuke T. Malignant transformation of adenomatous hyperplasia to hepatocellular carcinoma. Lancet 1990; 336: 11501153.
  • 39
    Tsuda H, Hirohashi S, Shimosato Y, Yoshida T, Terada M. Low incidence of point mutation of c-Ki-ras and N-ras oncogenes in human hepatocellular carcinoma. Jpn J Cancer Res 1989; 80: 196199.
  • 40
    Linardopoulos S, Street AJ, Quelle DE, Parry D, Peters G, Sherr CJ, Balmain A. Deletion and altered regulation of p16INK4 and p15INK4b in undifferentiated mouse skin tumors. Cancer Res 1995; 55: 51685172.
  • 41
    Okamoto A, Demetrick DJ, Spillare EA, Hagiwara K, Hussain SP, Bennett WP, Forrester K, et al. Mutations and altered expression of p16INK4 in human cancer. Proc Natl Acad Sci U S A 1994; 91: 1104511049.
  • 42
    Otterson GA, Kratzke RA, Coxon A, Kim YW, Kaye FJ. Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB. Oncogene 1994; 9: 33753378.
  • 43
    Shapiro GI, Edwards CD, Kobzik L, Godleski J, Richards W, Sugarbaker DJ, Rollins BJ. Reciprocal Rb inactivation and p!6 expression in primary lung cancers and cell lines. Cancer Res 1995; 55: 505509.